Targeting PIM kinase activity significantly augments the efficacy of cytarabine

Br J Haematol. 2012 Jan;156(1):129-32. doi: 10.1111/j.1365-2141.2011.08792.x. Epub 2011 Jun 21.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Combined Chemotherapy Protocols / pharmacology*
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cell Line, Tumor
  • Cytarabine / pharmacology*
  • Cytarabine / therapeutic use
  • Drug Synergism
  • Humans
  • Imidazoles / pharmacology*
  • Imidazoles / therapeutic use
  • Leukemia, Myeloid, Acute / drug therapy
  • Leukemia, Myeloid, Acute / metabolism
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinase Inhibitors / therapeutic use
  • Proto-Oncogene Proteins c-pim-1 / antagonists & inhibitors*
  • Pyridazines / pharmacology*
  • Pyridazines / therapeutic use

Substances

  • Imidazoles
  • Protein Kinase Inhibitors
  • Pyridazines
  • SGI 1776
  • Cytarabine
  • Proto-Oncogene Proteins c-pim-1
  • proto-oncogene proteins pim